glp-1 review article A new by Clifford J. Rosen, MD, and Julie R. Ingelfinger, MD, describes a new generation of treatment with receptor agonists for persons with obesity with or without diabetes or Glucagon-like peptide-1 receptor agonists (GLP-1

It has been shown that liraglutide, semaglutide, exendin-4, NLY01, and the GLP-1/GIP dual receptors agonist (DA3-CH, DA5-CH, DA-JC4, and DA-JC1), have neuroprotective properties in the in 1-methyl-4-phenyl-1,2,3,6-tetrahydropypridine (MPTP) mouse model [184,185,186,187,188,189,190,191]

There have been no head-to-head studies comparing the weight loss results of the weekly injection to the daily tablet formulation

It cannot determine how often the condition actually occurs, and the reports do not include detailed information about patients' health conditions or disease severity

Kane, MD, MPH , at Duke University School of Medicine and Dariush Mozaffarian, MD, DrPH, FACC , at Tufts University and Tufts Medical Center

There is therefore an unmet clinical need for therapeutics which effectively reduce ICP without further impacting on cognitive function